GSK3B and Miyoshi myopathy: In this context, we have recently demonstrated that FGF/FGFR inhibition in MM can affect the activation of downstream RAS and PI-3 K pathways, induces GSK-3β activation and leads to c-Myc degradation, as discussed in the next paragraphs.